ERBB2 and breast carcinoma: In Chinese patients with breast cancer undergoing NAC, HER2-low exhibits distinct characteristics and pCR rate in different HR subgroups, with its diminished sensitivity to chemotherapy being particularly crucial in HR-positive breast cancer.